| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experi...
B. Riley Securities analyst Mayank Mamtani initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and an...
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), today announced completion ...
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of ...